[Post-COVID-19 pulmonary sequla: longterm follow up and management]. / COVID-19 sonrasi akciger sekelleri: uzun dönem takip ve tedavi.
Tuberk Toraks
; 68(4): 419-429, 2020 Dec.
Article
in Turkish
| MEDLINE | ID: covidwho-1067902
ABSTRACT
Though it has been 8 months since the beginning of COVID-19 pandemic, number of cases and deaths are still seriously increasing. We still don't have enough evidence about the prognosis of patients who had COVID-19 pneumonia. In long term follow up we wonder if they will have rapid FVC decline, widespread fibrosis in computed tomography, loss in quality of life or increased mortality that we experience in idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonia or autoimmune interstitial lung diseases. However, in elderly patients less severe dysfunction or non-progressive-fibrosis can cause morbidity and mortality. Therefore, if we consider millions of people who are affected by COVID-19, even a rare complication can cause serious health problem in social scale. Because of the importance of this issue randomized controlled trials should be rapidly planned on post-COVID fibrosis, COVID associated thrombosis, risk factors, prevention and treatment (1). In this review, the frequency, clinical importance, prevention and treatment of possible long-term sequels of COVID-19 pneumonia (pulmonary fibrosis, pulmonary embolism and pulmonary hypertension) will be discussed.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Idiopathic Pulmonary Fibrosis
/
Pandemics
/
SARS-CoV-2
/
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
Turkish
Journal:
Tuberk Toraks
Year:
2020
Document Type:
Article
Affiliation country:
Tt.70353
Similar
MEDLINE
...
LILACS
LIS